Key Highlights

  • argenx's Phase 3 ALKIVIA trial for Vyvgart Hytrulo in autoimmune myositis achieved its primary objective.
  • The combined IMNM/DM group showed a statistically significant 15.4-point TIS advantage over placebo at 52 weeks.
  • The IMNM cohort saw significant benefit, while the smaller DM subgroup showed meaningful but not statistically significant results.
  • The safety profile remained in line with previous efgartigimod research.

argenx SE (NASDAQ: ARGX) announced that its Phase 3 ALKIVIA trial for Vyvgart Hytrulo in autoimmune myositis achieved its primary objective, with the combined IMNM/DM group demonstrating a statistically significant 15.4-point TIS advantage over placebo at 52 weeks.

What Happened

The smaller DM subgroup showed clinically meaningful results that lacked statistical significance, while the IMNM cohort saw significant benefit, all while maintaining a safety profile in line with previous efgartigimod research.

Market Reaction

The disclosed information does not include stock price or trading data for argenx following the Phase 3 ALKIVIA results.

Outlook

The split results between the IMNM and DM subgroups are likely to be a key focus for regulators and investors as argenx determines its regulatory strategy for Vyvgart Hytrulo in autoimmune myositis.